DSpace Repository

Response to: 'Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg.

Show simple item record

dc.contributor.author Pons-Estel, Bernardo A.
dc.contributor.author Bonfa, Eloisa
dc.contributor.author Soriano, Enrique R.
dc.contributor.author Cardiel, Mario Humberto
dc.contributor.author Izcovich, Ariel
dc.contributor.author Vázquez, Gloria
dc.contributor.author Alarcón, Graciela S.
dc.date.accessioned 2018-12-03T17:02:50Z
dc.date.available 2018-12-03T17:02:50Z
dc.date.issued 2018
dc.identifier.uri https://hdl.handle.net/20.500.12866/4306
dc.description.abstract We want to thank Dr Morton Scheinberg for his interest1 in our recent lupus guidelines communication.2 In his letter, he points out several concerns regarding belimumab which we had recommended at the same therapeutic level as other immunosuppressants for joint and skin manifestations. Few clarifications are needed. The development of our guidelines followed a rigorous methodology in which the evidence on effect estimates should come, when available, from randomised controlled trials (RCTs). We did not identify any clinical trial comparing belimumab against other immunosuppressants. Therefore, in considering this comparison, the development group had to rely on indirect evidence (the difference in belimumab effect against placebo and other immunosuppressants against placebo) or high risk of bias evidence (from observational studies). In this context, the panel agreed that the certainty that belimumab was better (or worse) than other immunosuppressants was low/very low and therefore decided not to recommend one over the others... en_US
dc.language.iso eng
dc.publisher BMJ Publishing Group
dc.relation.ispartof urn:issn:1468-2060
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject autoimmune diseases en_US
dc.subject belimumab en_US
dc.subject controlled study en_US
dc.subject drug efficacy en_US
dc.subject drug information en_US
dc.subject drug response en_US
dc.subject glucocorticoid en_US
dc.subject human en_US
dc.subject immunosuppressive treatment en_US
dc.subject Letter en_US
dc.subject observational study en_US
dc.subject placebo en_US
dc.subject practice guideline en_US
dc.subject priority journal en_US
dc.subject randomized controlled trial en_US
dc.subject systemic lupus erythematosus en_US
dc.subject treatment en_US
dc.title Response to: 'Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg. en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1136/annrheumdis-2018-214385
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.17
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.03

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account